Top 50 Biotech Startup Investors in Europe (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Bpifrance
VC Fund
|
109 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $757k–$34M |
|
SOSV
VC Fund
|
80 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Sofinnova Partners
VC Fund
|
79 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
64 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$39M |
|
UK Innovation & Science Seed Fund
VC Fund
|
64 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $458k–$14M |
|
Scottish Enterprise
VC Fund
|
60 | United Kingdom, United States, Switzerland | Grant, Seed | Biotechnology, Software, Health Care | $119k–$4.3M |
|
Parkwalk Advisors
VC Fund
|
56 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.2M–$45M |
|
Novo Holdings
VC Fund
|
55 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.9M–$135M |
|
Oxford Science Enterprises
VC Fund
|
51 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.4M–$168M |
|
SFC Capital
VC Fund
|
46 | United Kingdom, United States, Canada | Pre-Seed, Seed | Artificial Intelligence, Software, Information Technology | $131k–$2.2M |
|
Kurma Partners
VC Fund
|
41 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.7M–$98M |
|
Seventure Partners
VC Fund
|
38 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$63M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
36 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Enterprise Ireland
VC Fund
|
36 | Ireland, United States, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $494k–$12M |
|
Oxford Technology Management
VC Fund
|
35 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $33k–$7.9M |
|
Jonathan Milner
Angel
|
32 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Scottish Investment Bank
VC Fund
|
31 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7.5M |
|
Centre for the Development of Industrial Technology (CDTI)
VC Fund
|
31 | Spain, United States, France | Grant, Seed | Biotechnology, Health Care, Software | $170k–$15M |
|
BioInnovation Institute
VC Fund
|
31 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Seed | Biotechnology, Medical, Health Care | $495k–$5.2M |
|
Entrepreneurs First
VC Fund
|
30 | United Kingdom, United States, India | Pre-Seed, Seed, Series A | Artificial Intelligence, Software, Information Technology | $55k–$45M |
|
Future Planet Capital
VC Fund
|
29 | United Kingdom, United States, Spain | Seed, Convertible Note | Biotechnology, Health Care, Software | $688k–$5.5M |
|
Forbion Capital Partners
VC Fund
|
29 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
O2h Ventures
VC Fund
|
28 | United Kingdom, Hungary | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Pharmaceutical | $603k–$25M |
|
GO CAPITAL
VC Fund
|
28 | France, Canada, Israel | Seed, Series A | Biotechnology, Software, Health Care | $549k–$13M |
|
Catapult Ventures
VC Fund
|
27 | United Kingdom, United States, Israel | Seed, Series A | Health Care, Biotechnology, Medical | $150k–$26M |
|
Mercia Fund Managers
VC Fund
|
27 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $250k–$14M |
|
Epidarex Capital
VC Fund
|
26 | United Kingdom, United States, Germany | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $531k–$48M |
|
Chalmers Ventures AB
VC Fund
|
26 | Sweden | Pre-Seed, Seed | Software, Biotechnology, Information Technology | $5.8k–$2.3M |
|
IP Group
VC Fund
|
26 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$30M |
|
M Ventures
VC Fund
|
26 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Inveready
VC Fund
|
26 | Spain, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Information Technology | $439k–$14M |
|
Meusinvest (Noshaq)
VC Fund
|
24 | Belgium, France, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $137k–$31M |
|
Elaia
VC Fund
|
24 | France, United States, Spain | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.1M–$50M |
|
Karista
VC Fund
|
24 | France, United States, Finland | Seed, Series A, Series B | Software, Biotechnology, Health Care | $713k–$33M |
|
Omnes Capital
VC Fund
|
23 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$53M |
|
European Investment Bank
VC Fund
|
23 | France, Germany, The Netherlands | Debt Financing, Post-IPO Debt | Biotechnology, Health Care, Energy | $16M–$726M |
|
Northstar Ventures
VC Fund
|
23 | United Kingdom, United States, Indonesia | Seed, Series A | Software, Health Care, E-Commerce | $39k–$10M |
|
Archangels
VC Fund
|
23 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $1.3M–$8.3M |
|
Development Bank of Wales
VC Fund
|
23 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Manufacturing | $18k–$3.8M |
|
AdBio partners
VC Fund
|
22 | France, Spain, Belgium | Seed, Series A, Venture - Series Unknown | Biotechnology, Health Care, Pharmaceutical | $2.2M–$37M |
|
Oxford Capital
VC Fund
|
21 | United Kingdom, United States, France | Seed, Series A | Software, Health Care, Biotechnology | $1.5M–$16M |
|
HealthCap
VC Fund
|
21 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$92M |
|
Eos
VC Fund
|
21 | United Kingdom, Ireland, United States | Seed, Series A | Biotechnology, Health Care, Medical | $1.5M–$47M |
|
AlbionVC
VC Fund
|
21 | United Kingdom, United States, France | Series A, Seed | Software, Information Technology, Health Care | $2.2M–$19M |
|
Business Growth Fund
VC Fund
|
21 | United Kingdom, Ireland, United States | Venture - Series Unknown, Series A | Software, Manufacturing, Information Technology | $3.5M–$21M |
|
MIG Capital
VC Fund
|
21 | Germany, France, Austria | Series A, Series B | Biotechnology, Health Care, Software | $1.6M–$60M |
|
Portugal Ventures
VC Fund
|
21 | Portugal, United States, France | Seed, Pre-Seed | Software, Information Technology, Health Care | $107k–$2M |
|
CDP Venture Capital
VC Fund
|
21 | Italy, United States, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $483k–$23M |
|
Deepbridge Capital
VC Fund
|
21 | United Kingdom, Spain, Australia | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
Auriga Partners
VC Fund
|
20 | France, United States, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $2.2M–$33M |
| Access all 50 investors in Europe Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1459
- Round size: Seed $757k–$6.3M; Series A $3M–$34M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Cofarco — Official COFARCO twitter account. Commodity finance and trade credit insurance specialist.
- Hiqute Diamond — High quality diamond plates for high-end applications
- Tribun Health — Tribun Health provides a complete digital pathology platform for diagnosis, prognosis and biomarker analysis.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 329
- Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 610
- Round size: Seed $909k–$7M; Series A $3.5M–$39M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
- Coinlend — Coinlend - The Lending-Bot for Bitfinex & Liquid Genearate interest from your Bitcoin and Altcoin investments!
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 144
- Round size: Seed $458k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- MFX — MFX develops microfluidic-based platforms for cell and gene therapy development and manufacturing
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Halo X Ray Technologies — HALO X-ray Technologies - next generation X-ray diffraction technology for the aviation security, medical and process control markets.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 386
- Round size: Seed $381k–$4.3M; Grant $119k–$4.2M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- QuickBlock — QUICKBLOCK delivers training environments, deployable infrastructure and force protection solutions for defence and security organisations worldwide.
- Cirrus Logic — Cirrus Logic, Inc. is a premier supplier of high-precision analog and digital signal processing components for audio and energy markets.Founded in 1984, Cirrus Logic excels at developing complex chip designs where feature integration and innovation is a premium. Cirrus Logic has more than 1,000 patents that are key to our more than 700 productsserving more than 2,500 end customers globally, through both direct and distributor-based channel sales.
- Incremental Group — Incremental Group provides software consultancy and analytics services to clients in oil and gas, financial services, and the public sector.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 289
- Round size: Seed $1.2M–$4.8M; Series A $1.6M–$15M; Series B $2M–$45M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
- MoA Technology — We harness the principles of natural selection to accelerate discovery for better, safer herbicides so farmers can continue to feed the world.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 370
- Round size: Series A $9.9M–$133M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Tarveda Therapeutics — Developing Pentarins to make a difference in the treatment of patients with solid tumor malignancies
- Tarsa Therapeutics — Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 195
- Round size: Seed $1.4M–$12M; Series A $6.3M–$45M; Series B $13M–$168M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- AlveoGene — Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Scripta Therapeutics — Biology decoded, disease undone - modulating transcription factors to restore health
Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Pre-Seed, Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 578
- Round size: Seed $131k–$2.2M; Pre-Seed $173k–$846k
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $1.9M in 2019
Portfolio highlights
- Keylr — Services partner for property managers. Book reliable, top-rated professionals for your properties with e-props.
- Furbnow — Furbnow - Your companion for home improvements for the future
- Checkboard — Complete your identity verification and payments without the paperwork. Checkboard handles your ID, open banking, and payments from one app.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 142
- Round size: Seed $2.7M–$14M; Series A $3.8M–$98M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 247
- Round size: Series A $3.3M–$28M; Series B $3.4M–$63M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
- Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 104
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
- smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 665
- Round size: Seed $494k–$3.3M; Series A $2.2M–$12M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $1.1M in 2021
Portfolio highlights
- mAdme — mAdme Technologies is a digital communications channel that delivers rich and dynamic messages directly to mobile subscribers, with the highest engagement rates.
- Finovation Limited — Finovation Limited
- Touchtech Payments — At Touchtech Payments, believe in making industry changing and innovative technology.
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 110
- Round size: Seed $33k–$2.2M; Series A $786k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
- Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 62
- Round size: Seed $537k–$25M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 230+ centers worldwide.
- Nuclera — Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 216
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7.5M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Administrate — Manage instructor-led training with Administrate. Plan, schedule, communicate, resolve issues, and report on training operations from one platform.
The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed
- Geography: Spain, United States, France
Investor stats
- Total investments: 217
- Round size: Seed $576k–$5.8M; Grant $170k–$15M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- FuVeX — FuVeX is dedicated to the design, manufacture, and commercialization of drones. The vision of the members of FuVeX is to improve the way in which the great institutions and companies are related to the aeronautics. Moreover, the company's mission is to provide such institutions and companies with an aircraft that allows them to solve theirmonitoring or transportation needs by flying long distances in a safe, easy and legal way.
- Orga AI — Organ AI creates generative artificial intelligence that will help people. Its headquarters is located in Palma De Mallorca, Islas Baleares, Spain.
- Phoenix Foods — Phoenix Foods uses insect farming to solve the problems of organic waste management and the requirement for high-quality proteins in animal feed.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Seed
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 92
- Round size: Seed $532k–$1.6M; Pre-Seed $516k–$5.2M; Convertible Note $495k–$1.6M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 283
- Round size: Seed $724k–$7M; Pre-Seed $55k–$3.1M; Series A $6M–$45M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Juno Bio — Disrupted vaginal microbiomes can cause everything from recurrent infections to infertility. Get your comprehensive vaginal microbiome test and find out where you stand.
- Sourcepulse — Your early warning system for software delivery (YC S23)
- EverSettled — Navigate the probate process with confidence. We provide a free checklist, guidance, and support to help families find clarity in the chaos of loss.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 181
- Round size: Seed $688k–$5.5M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Unloq AI — Unloq is a Decision Intelligence Platform that turns your company data and live market signals into governed strategic recommendations. Approved, tracked, measured.
- Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 208
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $19M–$120M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 49
- Round size: Seed $603k–$7.5M; Series A $1.9M–$25M; Venture - Series Unknown $1.1M–$2.9M
- Lead/follow: 43% lead, 57% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: France, Canada, Israel
Investor stats
- Total investments: 139
- Round size: Seed $549k–$6.3M; Series A $2.1M–$13M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Lifeaz — Lifeaz saves lives by developing a new generation of connected, simpler, more reliable and smarter defibrillators.
- Axomove — Axomove specializes in the prescription of video-based physical exercises. The company's movement knowledge is used by health professionals to improve remote monitoring of their patients and to avoid Musculoskeletal Disorders (MSDs) at work.
- NeoXperiences — NeoXperiences develops technological solutions that bring audiences together around fun and interactive experiences.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 105
- Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Anello Photonics — Anello Photonics is a technology company developing a silicon photonic optical gyroscope to navigate, position, and motion track autonomous applications in challenging GPS-jammed and spoofed environments. The company's technology portfolio spans over 28 issued patents, and over 44 pending patents, and includes an AI-based sensor fusion engine.It serves the robotics, defense, construction, agriculture, and autonomous vehicles industries.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 139
- Round size: Seed $250k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Ben — Ben is the all-in-one platform for any company to personalise benefits and reward.Our secret? Marrying a modern software (SaaS) platform with per-employee Mastercards and financial infrastructure. That’s how Ben instantly adds employee choice to your existing benefits, unlocks access to hundreds of additional options through Ben Card, all whilesaving you time and money.
- Distil.ai — Distil.ai is a software platform that helps businesses to understand their customers’ behavior and identify buying signals.
- MRC Engineering — MRC Engineering Providing a different option to the UK Rail Industry for Telecoms Design. Nationally renowned design specialists who provide extraordinary ...
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 50
- Round size: Seed $531k–$8.5M; Series A $2.6M–$38M; Series B $2.4M–$48M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- RapidPulse — Explore RapidPulse for innovative stroke treatments and technologies. Book appointments or learn about our team and clinical trials.
- Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Pre-Seed, Seed
- Geography: Sweden
Investor stats
- Total investments: 249
- Round size: Seed $285k–$2.3M; Pre-Seed $5.8k–$318k
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- Ambidex AB — helps food retailers create new revenue streams on their refrigeration systems by stabilizing the electricity grid.
- Anferra — Turning hazardous steel waste into clean water and green energy.
- InfiniNode Technologies AB — InfiniNode is a semiconductor IP company that seeks to enable efficient data movement in future compute systems.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 206
- Round size: Seed $393k–$8.5M; Series A $2.4M–$30M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
- Slamcore — Positioning, mapping and perception | State-of-the-art visual SLAM turns sensor data into actionable, spatial understanding for your vehicles.
- Oxa — Autonomous Vehicle Software - Any Vehicle, Any Place, Any Time
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 174
- Round size: Seed $2.4M–$24M; Series A $5.6M–$50M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- ApoGen Biotechnologies — Explore fast payout casinos that deliver winnings instantly or under 24 hours. List of the best payout casinos to get same day winnings.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Inveready is a leading Spanish financial services firm focused on investment solutions and wealth management.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 203
- Round size: Seed $439k–$5.8M; Series A $1.6M–$14M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Voztelecom — VozTelecom develops software to enable Voice over Internet Protocol (VoIP) services over Internet. The company's products include miVoz.net, personal IP telephony service; intraVoz.net, local area network (LAN) IP telephony service with enhanced features; extraVoz.net, a hosted IP telephony service; vozConference.net, a hosted Web-conferenceservice with enhanced collaboration features; and wifiVoz.net, application that enables the usage of VozTelecom service through any wireless terminal. Voz has strategic alliances with Interxion, Cisco Systems, Iptel.org, SIP Phone, Jasomi Networks, Midworld Networks, and Endercom. The company was founded in 2003 and is headquartered in Cerdanyola, Spain.
- Inventia Kinetics — Inventia Kinetics specializes in the design, analysis, and manufacture of equipment and assembly tools for electronics sector.
- Telum Therapeutics — Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 78
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Series B $680k–$31M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: France, United States, Spain
Investor stats
- Total investments: 223
- Round size: Seed $1.1M–$9.9M; Series A $2.2M–$26M; Series B $4.2M–$50M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Hema.to — Hema.to provides fully automated, AI-powered blood cancer detection suggestions based on flow cytometry data.
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Stanley Robotics — Stanley Robotics is a DeepTech business helping the transportation and logistics industries digitalise and robotise outdoor operations.
Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: France, United States, Finland
Investor stats
- Total investments: 156
- Round size: Seed $713k–$6.3M; Series A $1.2M–$18M; Series B $2.5M–$33M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
- Advestigo — Advestigo S.A., a technology company, provides digital assets protection solutions. It offers theraography technology, which analyses digital content to generate content-based fingerprints; AdvestiCHECK, a software package that allows companies to monitor information technology networks and workstations; and AdvestiGUARD, a software package thatallows companies to monitor communication channels. The company was founded in 2002 and is based in Saint-Cloud, France. As of March 9, 2009, Advestigo S.A. operates as a subsidiary of Hologram Industries SA.
- Physikron — Physikron is a developer of mass spectrometry technologies used to improve the performance of tandem spectrometry. Its technologies offer proteomic analysis and dramatically improves the number of peptides and proteins identified during an LC/MS/MS acquisition that enable researchers to research in an enhanced way.
Omnes Capital takes a unique approach to renewable energy, transforming developers into independent power producers to provide green energy to millions.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 184
- Round size: Series A $3.5M–$41M; Series B $4.4M–$53M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation, and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Energy
- Stage:Debt Financing, Post-IPO Debt
- Geography: France, Germany, The Netherlands
Investor stats
- Total investments: 520
- Round size: Post-IPO Debt $18M–$726M; Debt Financing $16M–$352M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Ukrposhta — Ukrposhta sends and receives shipments from all over the world, as well as orders mail products sent to the most distant corners.
- IPT PowerTech — IPT PowerTech coverage, coupled with our extensive expertise in supply chain management, field implementation, and power systems, has made us one of the most capable companies in handling the most complicated and versatile projects in the MEA region and its neighboring countries.
- Santander Brasil — Banco Santander in Brazil, its largest division in Latin America and one of the world's most important, accounting for 50%.
Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 208
- Round size: Seed $39k–$2.1M; Series A $295k–$10M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
- NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
- Advanced Electric Machines — Our magnet free motors help manufacturers build more sustainable vehicles and products. See how we can help you today.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 85
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Bioliberty — Engineering the future of physical and occupational therapy.
- Earth Blox — Earth Blox provides a platform for analyzing geospatial data through a visual interface for environmental and land analysis. The system enables users to build workflows using satellite imagery and other earth observation datasets without requiring extensive coding knowledge. It supports applications such as deforestation tracking, carbonmonitoring, agriculture assessment, and land use analysis.The platform integrates data sources and processing tools to help users generate insights, automate analyses, and export results for reporting or further use. It also allows collaboration across teams by sharing workflows and outputs within a unified environment. Earth Blox supports organizations working with geospatial intelligence by simplifying access to large-scale environmental data and analysis tools.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Manufacturing
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 248
- Round size: Seed $360k–$3.3M; Debt Financing $18k–$3.8M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Wagonex — Car subscription is the new, all-inclusive, flexible alternative to leasing. No large downpayment and a single fixed monthly payment. Just add fuel and go.
- Jehu Group — The Jehu Group is a third generation family owned business with over 80 years of successful trading history.We mange our operations on a day-to-day basis through three trading subsidiaries. Each subsidiary is supported by Jehu Group Limited which provides finance, HR, technical and procurement functions.In all of our markets, we position ourselvesas a dynamic and bespoke alternative to national contractors and house builders and are proud of our strong reputation in the market place.
- Reacta Biotech — Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 32
- Round size: Seed $2.2M–$18M; Series A $18M–$37M; Venture - Series Unknown $2.2M–$16M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $116M in 2021
Portfolio highlights
- Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 150
- Round size: Seed $1.5M–$3.9M; Series A $3.2M–$16M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $56M in 2015
Portfolio highlights
- Moneybox — Moneybox is the simple way to save, invest, buy your first home, and combine your old pensions - all with one award-winning app. Download now.
- Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
- Oxford Quantum Circuits — Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 133
- Round size: Series A $5.7M–$85M; Series B $12M–$92M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- Neobiomics — Neobiomics is a Swedish life-science company that develops nutritional products for preterm infants and neonatal care. Its best-known products include ProPrems® and NeoMega36®.
- CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Eos invests in, & commercialises, science & technology, from local seed-stage to global scale, with a focus on improving lives.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 43
- Round size: Seed $1.5M–$11M; Series A $1.6M–$47M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- TaiSan — A polymer-electrolyte sodium battery for the e-bike and scooter fleet.
- Nami Surgical — Despite advances in robotic surgery, integrated ultrasonic energy remains unavailable in wristed robotic surgical systems.
- Scarlet Therapeutics — Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform.
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 175
- Round size: Seed $2.2M–$12M; Series A $3.9M–$19M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- uMotif — uMotif provides the most modern eCOA/ePRO and eConsent platform designed to power clinical and real-world research.
- Hussle — Gym membership with total flexibility. Gym passes to no contract gym memberships that you can use in thousands of gyms across the UK. Gym and swim wherever you want to. Stop and start whenever you like.
- Gravitee — Open Source API Management Platform - Gravitee
BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Venture - Series Unknown, Series A
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 416
- Round size: Series A $3.9M–$21M; Venture - Series Unknown $3.5M–$19M
- Lead/follow: 85% lead, 15% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- TMT ID — A leading provider of global mobile and device intelligence. We power leading identity providers, A2P SMS messaging companies and financial organisations.
- UK Flooring Direct — Transform your home with UK Flooring Direct. Shop wood, laminate, & vinyl flooring at great prices with fast UK delivery & expert advice.
- Thames Card Technology —
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Germany, France, Austria
Investor stats
- Total investments: 97
- Round size: Series A $2.2M–$40M; Series B $1.6M–$60M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $70M in 2014
Portfolio highlights
- NcodiN — The High Performance Computing (HPC) and ArtificiaI Intelligence (AI) era requires unprecedented computing capabilities. With this in view, industry is heading towards zettascale supercomputers, based on >100k processing units. Chiplets-based disaggregated processors and memory-centric computing architectures are taking over and require an ever more intensive communication between dies. Thus, today interconnect bottleneck is the main
- GlassPoint Solar — GlassPoint provides solar steam generators to the oil and gas industry for applications such as Enhanced Oil Recovery. It replaces gas-fired steam generation with solar, GlassPoint can reduce EOR gas consumption by up to 80 percent. The company was founded in 2008 and headquartered in Fremont, California.
- Zadient Technologies — Zadient produces semiconductor manufacturing materials that are critical for the entire silicon carbide (SiC) value chain
Verticals:Enterprise, SaaS, Security, Networks, AI, VR/AR, Marketplace, Blockchain, Internet of Things, New materials, Electronics, Robotics, Cleantech, Agrotech, Seatech, Therapeutics, Digital Health, Diagnostics, Innovative Accommodation, Tourist Entertainment Companies, Tour Operators, Wine, Nautical and Equestrian Tourism, Theme ParksMobile, Robotics Founded in 2012, Portugal Ventures is a venture capital firm based in Porto, Portugal. The firm is a part of the Banco Português de Fomento group. The firm seeks to invest in pre-seed, seed and series A stages
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed
- Geography: Portugal, United States, France
Investor stats
- Total investments: 295
- Round size: Seed $110k–$2M; Pre-Seed $107k–$547k
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — last raise in 2011
Portfolio highlights
- AddVolt — AddVolt is a technology based company that tackles markets where there is a high potential for diesel costs reduction through the generation of solar and kinetic energy, while other secondary savings are generated (e.g. maintenance).
- Unlockit — Unlockit will offer to public and governmental bodies the guarantee that everything within a real estate transaction is recorded, meaning better industry regulation, more taxes and public fees collected, and less overall fraud and money laundering activities.
- Logical Safety — IoT safety for a safer, more productive workforce
CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Italy, United States, United Kingdom
Investor stats
- Total investments: 295
- Round size: Seed $483k–$7.7M; Series A $3.3M–$23M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $197M in 2021
Portfolio highlights
- Evja — Evja supports growers in optimizing the management and monitoring of irrigation, nutrition and protection of their crops through the use of OPI, the most advanced system for precision agriculture .
- Mopso — Discover Mopso's anti money laundering detection system. Visit our website and try a 30 minutes free demo with one of our experts.
- ALLSIDES — Covision Media specializes in creating high-quality, relightable 3D models using their industrial 3D scanners. These scanners capture detailed surface information and PBR textures, and are designed for easy integration into virtual environments.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Spain, Australia
Investor stats
- Total investments: 91
- Round size: Seed $152k–$2.4M; Series A $2M–$15M
- Lead/follow: 69% lead, 31% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- upLYFT — upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records.
- GeneralPractice.AI — GeneralPractice.AI - Infusing Artificial Intelligence into the Fabric of General Practice
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 128
- Round size: Series A $2.2M–$14M; Series B $3.8M–$33M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Availpro — D-EDGE empowers 17,000+ hotels to boost revenue with CRS, Booking Engine, Channel Manager, hospitality-focused websites & digital marketing solutions.
- Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
- Bonitasoft — Bonita helps businesses automate workflows, boost efficiency, and turn complexity into a competitive edge. Unlock the power of process automation today!
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Europe Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!